A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results
Age and Ageing · 03.08.2026 · 55 (8)
DOI: 10.1093/ageing/afag239 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, online erschienen am 18.08.2026. Verfasst von Federica Bianchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Palliative Medicine Division, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, GE, Switzerland. Hauptthemen laut MEDLINE: Dronabinol, Dementia, Cannabidiol, Psychomotor Agitation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Behavioural and psychological symptoms of dementia (BPSD) are frequent in patients with severe dementia and represent a major clinical challenge. Cannabinoid-based medications (CBM) have been proposed as a possible therapeutic option, but clinical evidence is still limited.
Methods
We performed a multicenter, randomised, double-blind, placebo-controlled crossover trial in five long-term care facilities in Geneva, Switzerland. Patients with severe dementia received oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) oil (1:2 ratio, up to 20 mg/40 mg daily) and placebo in two 8-week periods separated by a 1-week washout. The primary outcome was agitation measured by the Cohen–Mansfield Agitation Inventory (CMAI). Secondary outcomes included behavioural scales, pain, as-needed psychotropic medication use and safety.
Results
Twenty-five patients (average age 83 years) were randomised, and nineteen completed both study periods. No significant difference was observed between active treatment and placebo for the CMAI and other main behavioural outcomes. However, the use of pro re nata psychotropic medications was significantly lower during the active treatment period. The treatment was well tolerated, and no serious adverse events related to the study drug were observed.
Conclusions
In this real-life crossover study, THC/CBD oil did not show superiority over placebo in reducing agitation in severe dementia. However, it was safe and associated with a significant reduction in the use of as-needed psychotropic medications prescribed for behavioural and psychological symptoms of dementia. CBM may represent a possible adjunctive option in selected patients, but further studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Palliative Medicine Division, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, GE, Switzerland.
- Fondation pour l'accueil et l'hébergement de personnes âgées, Geneva, GE, Switzerland.
- Faculty of Medicine, University of Geneva, Geneva, GE, Switzerland.
- Faculty of Medicine, Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, University of Geneva, Geneva, GE, Switzerland.
- Faculty of Medicine, Department of Rehabilitation and Geriatrics, University of Geneva, Geneva, GE, Switzerland.
ORCID-Profile: Federica Bianchi
Zitieren
APA
Bianchi, F., Broers, B., Desmeules, J. A., Langlois, A., Wampfler, J., Curtin, F., & Pautex, S. (2026). A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results. Age and Ageing, 55(8). https://doi.org/10.1093/ageing/afag239
Vancouver
Bianchi F, Broers B, Desmeules JA, Langlois A, Wampfler J, Curtin F, et al. A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results. Age and Ageing. 2026;55(8). doi:10.1093/ageing/afag239
BibTeX
@article{Bianchi2026,
author = {Bianchi, Federica and Broers, Barbara and Desmeules, Jules Alexandre and Langlois, Angeline and Wampfler, James and Curtin, François and Pautex, Sophie},
title = {A randomised, double-blind, placebo-controlled crossover trial on cannabinoid-based medication for behavioural disorders in old patients with severe dementia: the study results},
journal = {Age and Ageing},
year = {2026},
volume = {55},
number = {8},
doi = {10.1093/ageing/afag239}
}
EUVIMED